We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Brain Cancer

Expert Opinion / Cases · July 23, 2021

59 Year Old Male, KPS 90, Initially Diagnosed With a Right Temporal Glioblastoma

Written by
Martin C. Tom MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • ruofan huang

    clinical trials


  • Alex Y

    Run liquid biopsy RGCC on fresh tumor or blood & treat accordingly to sensitivity. Rego can be be an option but dosage must be lowest as RPLS is possible same as with avastin. Summary GENE MARKERS ARE NEEDED to further elucidate correct chemotype for this patient


  • Dorothy-Myra Sackey

    treat post operative necrosis


  • Tolga Tuncer

    1) Why was the adjuvant TMZ only 3 mos? 2) Why did an unmethylated GBM NOT get Novo TTF-1 in adjuvant or concurrent setting 3) Candidate for AGILE study?


  • Al Musella

    1. FTB map. If it shows likely tumor, stereotactic radiosurgery to the new lesion, or LITT. 2. Optune 3. Val-083. Possibly via the AGILE study but might be better to get it on compassionate use along with Optune. 4. Viral therapy. Maybe PVSRIPO + Pembrolizumab.


  • Sep 21, 2021

    Pending Moderator approval.
    Delete

Further Reading